- Home
- MYND vs TXMD Comparison
MYND vs TXMD Comparison
Compare MYND & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MYND | TXMD |
|---|---|---|
| Founded | 1998 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.9M | 21.4M |
| IPO Year | 2017 | 2012 |
Fundamental Metrics
Financial Performance| Metric | MYND | TXMD |
|---|---|---|
| Price | $0.24 | $1.77 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 204.0K | 18.2K |
| Earning Date | 08-27-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 73.68 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $1,761,000.00 |
| Revenue This Year | N/A | $207.74 |
| Revenue Next Year | N/A | $2.15 |
| P/E Ratio | ★ N/A | $92.50 |
| Revenue Growth | N/A | ★ 35.25 |
| 52 Week Low | $0.00 | $1.11 |
| 52 Week High | $0.72 | $2.95 |
Technical Indicators
Market Signals| Indicator | MYND | TXMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 28.20 |
| Support Level | N/A | N/A |
| Resistance Level | $0.35 | $2.16 |
| Average True Range (ATR) | 0.06 | 0.07 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 65.43 | 16.13 |
Price Performance
Historical ComparisonAbout MYND Mynd.ai Inc.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.